Cytyc Gains Preterm Birth Diagnostic, Drug In $356 Mil. Adeza Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Cytyc is banking on its established women's health sales force to maximize the value of its $356 million purchase of Adeza Biomedical and its principal product Full Term, a diagnostic for preterm birth risk